Related Experiment Videos
[Nephrotoxicity of cisplatin]
1Clinique de Néphrologie et Unité d'Hémodialyse, HIA du Val-de-Grâce, Paris.
Annales D'Urologie
|January 1, 1992
Summary
Cisplatin chemotherapy for testicular tumors showed no significant kidney damage in a 5-year follow-up study. This finding suggests cisplatin
Area of Science:
- Oncology
- Nephrology
- Pharmacology
Context:
- Cis-diamminodichloroplatinum (cisplatin) is a cornerstone antineoplastic agent for testicular tumors.
- Cisplatin administration carries a risk of nephrotoxicity, including elevated creatinine, acute renal failure, and end-stage renal disease.
- Monitoring renal function is crucial for patients receiving cisplatin-based chemotherapy.
Purpose:
- To evaluate the long-term nephrotoxic effects of cisplatin-based chemotherapy in patients with malignant testicular tumors.
- To assess renal function and identify any instances of acute or delayed renal failure post-treatment.
Summary:
- A cohort of twelve patients with malignant testicular tumors received cisplatin-based chemotherapy (490–2,275 mg cumulative dose).
- Patients underwent long-term nephrological follow-up for an average of 56 months post-treatment.
- No cases of immediate or delayed acute renal failure or significant deterioration in renal function were observed during the follow-up period.
Impact:
- This study suggests that cisplatin chemotherapy, when administered with appropriate precautions, may not lead to significant long-term renal impairment in testicular cancer patients.
- Findings support the continued use of cisplatin in testicular cancer treatment while emphasizing the importance of vigilant nephrological monitoring.
- Provides valuable data for oncologists and nephrologists regarding the renal safety profile of cisplatin in this patient population.